04:27 PM EDT, 05/15/2026 (MT Newswires) -- Rani Therapeutics ( RANI ) reported Q1 net loss Friday of $0.04 per diluted share, narrowing from a loss of $0.22 a year earlier.

Four analysts polled by FactSet expected a loss of $0.05.

Revenue for the quarter ended March 31 was $1.7 million, compared with $172,000 a year ago.

Four analysts surveyed by FactSet expected $1.1 million.

The company said that Svai Sanford has decided to step down as Rani Therapeutics' ( RANI ) chief financial officer and will transition from his role following the appointment of a successor.